Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Colorectal Neoplasms 64Colonic Neoplasms 19Rectal Neoplasms 12Esophageal Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Cholangiocarcinoma 7Squamous Cell Carcinoma of Head and Neck 6Pancreatic Neoplasms 6Breast Neoplasms 6Colorectal Cancer Metastatic 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Head and Neck Neoplasms 4Ovarian Neoplasms 3Inflammatory Breast Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Recurrence 2Prostatic Neoplasms 2Lung Neoplasms 2Glioma 2Gastrointestinal Neoplasms 2Carcinoma 2Biliary Tract Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1

Interventions

telotristat ethyl 3telotristat 1lutetium Lu 177 dotatate 1alpha-methyltryptophan 1Panitumumab 1Octreotide 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Serotonin Syndrome × Panitumumab × Clear all
NCT01172717 2013-07-26

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Boston Medical Center

Phase 2 Withdrawn
Endocrine

Carcinoid Tumor, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡